Biotech ETFs Rise on AI-Driven Growth in the Industry

lunes, 16 de marzo de 2026, 11:33 am ET1 min de lectura
GILD--
MRNA--
VRTX--

Biotech ETFs are leveraging AI to accelerate clinical trials, personalize patient care, and enhance diagnostic accuracy, creating opportunities for profitability and growth. Firms like Gilead Sciences, Vertex Pharmaceuticals, and Moderna are harnessing machine learning to advance gene-editing technologies and develop personalized cancer vaccines. The global biotechnology sector is expected to follow a strong growth trajectory through 2026, fueled by an aging demographic and escalating healthcare demands.

Biotech ETFs Rise on AI-Driven Growth in the Industry

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios